Key result
Metabolic syndrome in COPD patients is linked to a ~5-fold higher frequency of postcovid syndrome.
Why the study?
To analyze the clinical manifestations and frequency of postcovid syndrome in COPD patients depending on the presence of metabolic syndrome.
Does the presence of metabolic syndrome increase the frequency and severity of postcovid syndrome in patients with COPD?
Cohort (n=222)
Does the presence of metabolic syndrome increase the frequency and severity of postcovid syndrome in patients with COPD?
Absolute Event Rate: 34.3% vs 6.7%
p-value: p=<0.05
The presence of metabolic syndrome in COPD patients significantly increases the frequency and severity of postcovid syndrome, including prolonged symptoms and increased COPD exacerbations.
May flag COPD patients with metabolic syndrome for closer post-COVID follow-up; leaves open causal links and intervention effects.
Objective: to analyze the clinical manifestations and frequency of postcovid syndrome in COPD patients, depending on the presence of metabolic syndrome. Materials and methods. There were 222 patients under outpatient supervision for a year after the new coronavirus infection (NCI): group I – 15 patients with COPD without MS, group II – 155 patients with COPD with MS. Group III (comparison) - 52 patients with MS without COPD, comparable in age and gender. Patients were included in the study as NCI became ill. During visits after 6 and 12 months, a comprehensive examination was carried out with an assessment of complaints, objective status, and a quality of life questionnaire; the HADS questionnaire, the frequency of exacerbations of COPD, blood oxygen saturation (SaO2), spirometry, 6-MWT (exercise tolerance), laboratory tests (CBC, biochemical blood analysis); chest CT; echocardiography. All patients filled out a questionnaire for the primary self-assessment of the health of patients who had undergone NCI. This study was conducted in accordance with the principles of the Helsinki Declaration; written informed consent was obtained from all patients before being included in the study. Results. Postcovid syndrome is more often detected in patients of group II (34.3%; p<0.05), less often in group I and III (6.7% and 18.4%, respectively). When assessing the symptoms of NCI in COPD patients with MS, even after a year of follow-up, the following prevailed: weakness (81.1%), subfebrility (48.5%), pain in the heart area (40.1%). When analyzing the psychoemotional status, it was noted that in patients with MS on the background of COPD, the level of personal and situational anxiety and depression in the post-covid period increased 2.5 times and was maximally expressed in the long-term period (a year after the NCI). The greatest impact of the transferred NCI had on the aggravation of the degree of dyspnea in group II patients after 6 and 12 months (p<0.05) and an increase in the frequency of exacerbations (p<0.05). Conclusion: The presence of MS in patients with COPD causes more frequent development of postcovid syndrome, which requires mandatory medical correction. Of the clinical manifestations of NCI, weakness, muscle pain, prolonged subfebrility with night sweats, anxiety and depressive disorders persisted for the longest time. The course of COPD was characterized by an increase in the number of exacerbations.
No takes yet. Share an insight, caveat, or question.
K.V. et al. (2023) conducted a cohort in Postcovid syndrome in COPD patients (n=222). Metabolic syndrome vs. COPD without metabolic syndrome and metabolic syndrome without COPD was evaluated on Frequency of postcovid syndrome (p=<0.05). Metabolic syndrome in COPD patients was associated with a significantly higher frequency of postcovid syndrome compared to COPD patients without metabolic syndrome (34.3% vs 6.7%; p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: